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To test the efficacy and safety of amoxycillin/clavulanate (Augmenting 102 hospital
patients with laparoscopically confirmed acute salpingitis were treated with paren-
teral amoxycillin/clavulanate (l-2g qid for three days) followed by oral amoxycillin/
clavulanate (two tablets of 625 mg tid for a further six days). Bacteriological samples
were obtained from the cervix uteri and the pouch of Douglas. One hundred patients
were assessable for clinical outcome using several variables including pain scores.
Amoxycillin/clavulanate alone was effective in 95 patients (95%). Three patients
(3%) responded to amoxycillin/clavulanate with marked improvement but another
antibiotic was subsequently added to their treatment regimen. Treatment failed in
two patients. At follow-up two weeks after hospital discharge, three patients (3-8%)
had relapsed or were re-infected. Adverse drug events included one case of drug
fever, one case of rash and one case of severe diarrhoea. Treatment was stopped in
all three cases. Gastrointestinal reactions, mainly mild diarrhoea, were seen in 31
patients. No clinically relevant changes in haematological or clinical chemical indices
were attributable to the amoxyciUin/clavulanatc treatment. We conclude that
amoxycillin/clavulanate is a clinically effective and safe treatment for acute
salpingitis.
Introduction
Amoxycillin/clavulanate (Augmentin) is an association of amoxycillin and the /?-
lactamase inhibitor clavulanic acid (used as potassium clavulanate). The antimicrobial
spectrum of amoxycillin is broadened by the clavulanic acid to include many (i-
lactamase-producing strains of both Gram-positive and Gram-negative species (Fuchs
etal., 1983; Deforges, Soussy & Duval, 1984; Slocombe etal., 1984). Amoxycillin/
clavulanate is active against Neisseria gonorrhoeae (including /Mactamase-producing
strains) and Gram-positive and Gram-negative anaerobes (including Bacteroides
fragilis). Both amoxycillin and clavulanate have been shown to penetrate readily into
the pelvic peritoneal cavity (Houang, Colley & Chapman, 1985).
The activity of amoxycillin/clavulanate against Chlamydia trachomalis in vivo is not
yet well defined. Eradication of Ch. trachomatis by an appropriate dosage of amoxy-
cillin has been demonstrated in men with gonococcal and non-gonococcal urethritis
(Bowie, Alexander & Holmes, 1981; Csango, Gundersen & Martinsen, 1985). Eradica-
tion from the cervix of pregnant women by amoxycillin was demonstrated in a recent
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study (Crombleholme etal., 1988), where amoxycillin proved to be at least as effective
as erythromycin. In-vitro activity of amoxycillin against Ch. trachomatis has been
demonstrated by several investigators (Kramer, Cleeland & Grunberg, 1979; Bowie
etal., 1981; Hobson etal., 1982; Bowie, 1986; Orfila & Haider, 1988).
Reports of the treatment of salpingitis with amoxycillin/clavulanate have been
encouraging (Mayer, Jeschek & Kowatsch, 1983; Ciraru-Vigneron etal., 1986).
Monotherapy with amoxycillin/clavulanate would therefore seem to be an appropriate
choice for the treatment of acute salpingitis.
Patients and methods
Study population
Patients admitted to the Department of Gynaecology of the University Hospital of
Zurich from May 1984 to December 1987 with clinically suspected salpingitis were
candidates for the trial and were subjected to laparoscopy.
Patients in whom the diagnosis of acute salpingitis could not be confirmed were
excluded from further evaluation. Patients were also excluded from the trial if they had
been treated with one or more antibiotics other than amoxycillin/clavulanate for less
than 48 h before hospital admission (since this period of treatment would be too short
to assess the response), if they had a history of penicillin allergy, if they were in renal or
hepatic failure, or if they were suffering from immune deficiency.
Treatment
Treatment with amoxycillin/clavulanate was started promptly after laparoscopic
confirmation of the diagnosis but before the results of culture were available. Initially
amoxycillin/clavulanate 1-2 g iv was given qid until a marked improvement of the
patient's condition occurred. During parenteral treatment the patients had strict bed
rest. Therapy was then continued with amoxycillin/clavulanate tablets, 2 x 625 mg tid,
until clinical recovery was almost complete or failure to respond to amoxycillin/
clavulanate made a change of therapy necessary.
Clinical methods
The laparoscopic techniques used and the criteria for the laparoscopic diagnosis and
classification of the degree of severity of acute salpingitis were as described by Jacobson
& Westrom (1969) and Ripa etal. (1980). The severity was classified as 'mild',
'moderate' or 'severe'. This rating was not used to determine the subsequent thera-
peutic regimen (Monif, 1982).
The clinical outcome was assessed by daily examination of the patient. Pain was
assessed by two different scores. At the beginning and end of treatment we scored by
bimanual examination of the pelvis (Scoring System A). To avoid repeated pelvic
examination, abdominal examination was carried out for assessment during therapy
(Scoring System B). The criteria used in Systems A and B and their score ranges are
listed in Table I. The definitions for 'cure', 'markedly improved' and 'failure' are shown
in Table II. Cases where therapy had to be stopped within three days because of an
adverse event were considered unassessable for clinical outcome. A clinical follow-up
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Table L Criteria of scoring systems A and B.
1. Scoring system A (bimanual examination of the pelvis)
Range of score (points)
(a) tenderness of the lower or whole abdomen 0-3
(b) rebound tenderness 0-3
(c) pain on motion of the cervix " 0-3
(d) adnexal tenderness on left side 0-3
(e) adnexal tenderness on right side 0-3
Total 0-15
2. Scoring system B (abdominal examination)
Range of score (points)
(a) abdominal pain 0-3
(b) abdominal pain when moving 0-3
(c) abdominal pain on pressure 0-3
Total 0-9
Pain ratings (points): 0, No pain.
1, Discomfort was not evident from the facial expression. Examiner had to ask if it
hurt, and patient indicated that it did.
2, Discomfort was not evident but easily elicited by minimal pressure/motion.
3, Discomfort was evident and easily aggravated by minimal pressure/motion.
examination was done two weeks after the end of treatment, and pain was assessed by
bimanual examination of the pelvis.
Laboratory methods
In each case specimens were taken from the cervical canal and the pouch of Douglas
for bacteriological examination. Specimens intended for general bacteriological exam-
ination were transported in Stuart's Medium in the case of swabs and by the Portagerm
System (Biomerieux, France) in the case of liquid specimens. Culture and identification
of bacteria were performed aerobically and anaerobically according to standard
procedures (Holdeman, Cato & Moore, 1977; Lennette etal., 1985). Specimens for
detection of Ch. trachomatis were collected and examined by direct immunofluores-
cence staining as described in the MicroTrak Kit (SYVA Merck). Smears in which ten
or more chlamydial organisms could be seen were reported as positive, and when two
Table U. Definitions for the assessment of pain.
Scoring system B
0
More than 0, but not more than one
third of the score before treatment
Range: 1-3
Score worse than "markedly improved"
Cure
Markedly
improved
Failure
Scoring system A
0-1
More than 1, but not more than
one third of the score before
treatment
Range: 2-5
Score worse than "markedly
improved"
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to nine were seen as presumptively positive. Smears were not reported negative unless
typical cells could be seen.
Haematological and clinical chemical investigations were carried out before and after
treatment with amoxycillin/clavulanate to detect any adverse events.
Results
One hundred and two women entered the study. One hundred were assessable for
clinical outcome. Their ages ranged from 17 to 47 years with a mean age of 26 years
and a modal age of 23-24 years. The infection was classified as mild in 44 (43-1%)
cases, moderate in 41 (40-2%) cases and severe in 17 (16-7%) cases. In 86 (84-3%)
patients the infection had been present for seven days or less, in 12 (11-8%) patients the
duration of symptoms was eight to fourteen days, and in four cases the duration was
unknown (Table III).
Twenty patients had been pre-treated with an antibiotic. All of them had failed to
respond after treatment for at least two days. The percentage of patients with positive
bacteriological findings was somewhat higher in the group of patients without pre-
treatment (68-3% vs 60-0%), but the difference was not statistically significant (P <
0-05).
The dosages and durations of treatment with amoxycillin/clavulanate are shown in
Table IV. The mean duration of parenteral treatment was 3-0 days, while that of the
oral treatment was 6-4 days. The mean total duration of amoxycillin/clavulanate
treatment (oral and parenteral) was 9-4 days.
The bacteriological findings are summarized in Table V. The most frequent isolates
were group B /?-haemolytic streptococci. All of these were isolated from the cervix.
Coagulase-negative staphylococci were isolated almost as often, but always from the
pouch of Douglas. Of all isolated or detected organisms, 59-4% were found in the
cervix, 49-5% in the pouch of Douglas, and 8-9% in both.
The clinical assessment of pain at the end of treatment is summarized in Table VI.
When assessed by Score A, which is more sensitive than B, 80 (800%) patients were
free of pain and therefore classified 'cured'. Eighteen patients were 'markedly
improved'. Treatment failed in two patients, and two were unassessable. All cases
assessed 'markedly improved' are shown in Table VII. Fifteen of the 18 patients listed
here did not need subsequent therapy, so that amoxycillin/clavulanate alone was
effective in 95 (950%) patients (TableVIII). Three patients improved markedly but
subsequent therapy was necessary. In two cases a second antibiotic was necessary
because of treatment failure. In two cases, one clinically cured and the other markedly
improved, another antimicrobial agent was added because of a persistently high
erythrocyte sedimentation rate (ESR). In three cases the initial therapy had to be
changed because of an early adverse event. The eight cases in whom subsequent
therapy was necessary are listed in Table IX.
The clinical courses as reflected by the leucocyte count, the ESR, the oral/axillary
temperature and the pain scores A and B are shown in Figures 1 and 2. The percentages
of patients in whom leucocyte count, ESR and the temperature were above normal at
the various time points are shown in Figure 1. The mean pain scores A and B,
expressed as percentage of the maximal score, are given in Figure 2. At clinical follow-
up 79 patients were assessable. Seventy-six (96-2%) were still clinically cured. Three
(3-8%) had a relapse (or re-infection). Twenty-three patients were unassessable, either
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Table ID. Duration of clinical symptoms
before treatment
Duration (days) No. of cases
1-3
4-7
8-14
Unknown
59 (57-8%)
27 (26-5%)
12(11-8%)
4 (3-9%)
Table IV. Dosage and duration of treatment with
amoxycillin/clavulanatc
Mode of
treatment
Parenteral
Oral
Parenteral + oral
TableV. Results of the 68
Organism
/J-Hacmolytic streptococci group B
Coagulase-negative staphylococci
N. gonorrhoeae
Ch. trachomatis
Escherichia coli
Staphylococcus aureus
Gardnerella vaginalis
Enterococcus fdecalis
Propionibacterium spp.
Viridans streptococcus
Corynebacterhan spp.
Mycoplasma spp.
Acinetobacter calcoaceticus ~
/J-Haemolytic streptococci group A
Bacillus spp.
Total
Dosage regimen
1-2 g qid
1250 mg tid
see above
Duration (days)
mean range
3-0 1-6
6-4 1-10
94 4-11
positive findings (cervix and pouch of Douglas)
No.
positive cervix
uteri
23 23
22 —
14 14
9 6
7 2
5 5
4 4
4 2
3 —
3 1
2 1
2 2
1 —
1 —
1 —
Site of positive findings
pouch of cervix uteri and
Douglas pouch of Douglas
22 —
6 6
4 1
6 1
1 1
— —
2 —
-5
2 —
I
— —
1 —
1 —
i
101 60(594%) 50(49-5%) 9(8-9%)
Table VL Clinical assessment by pain scores A
No.
score A
and B at end of treatment
of patients
score B
Assessment (bimanual examination) (abdominal examination)
Cure
Markedly improved
Failure
Unassessable
80 (800%)
18 (18-0%)
2 (2-0%)
2
87 (87-0%)
11 (11-0%)
2 (2-0%)
2
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Table VII. The cases assessed as 'markedly
Severity of
infection
Moderate
Severe
Moderate
Mild
Mild
Mild
Mild
Moderate
Mild
Mild
Moderate
Severe
Mild
Moderate
Severe
Mild
Severe
Moderate
Mild 8
Moderate 6
Severe 4
Bacteriology
G. vaginalis
coagulase negative staphylococci
—
mycoplasmas
Acinetobacter, /?-haemolytic
streptococci B
—
coagulase negative staphylococci,
/?-haemolytic streptococci B
coagulase negative staphylococci
Ch. trachomatis
coagulase negative staphylococci,
G. vaginalis
—
/?-haemolytic streptococci B
Propionibacterium
N. gonorrhoea*
—
—
coagulase negative staphylococci
0-haemolytic streptococci B,
coagulase negative staphylococci
negative findings S
positive findings 13
oL
improved' at end of treatment
Second course
of antimicrobial Oinical
therapy follow-up
— unassessable
thiamphenicol relapse
— cure
thiamphenicol unassessable
— cure
— cure
— cure
— cure
doxycycline unassessable
— unassessable
— unassessable
— cure
— cure
— cure
— cure
— cure
— unassessable
— cure
unassessable 6
cure 11
relapse 1
because they did not present for follow-up or, in three cases, were treated with an
additional antibiotic.
Eight of the nine cases with chlamydial infections were 'cured' at the end of
treatment, and one 'markedly improved' (perihepatitis with persistence of pain in the
liver region). At follow-up all seven assessable patients were clinically cured.
Full haematological and clinical chemical investigations were done in all patients at
the beginning and end of treatment. Slight elevations in serum transaminases were seen
in some patients but were considered to be clinically insignificant; in all cases the
transaminase levels remained within their normal ranges.
Table VTJI. Efficacy of amoxycillin/clavulanate
Clinical outcome No. of patients
Amoxycillin/clavulanate alone effective
Markedly improved, but subsequent therapy necessary
Failure
Unassessable
95 (95-0%)
3 (3-0%)
2 (2-0%)
2
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Admission Doy3 Doy6 Discharge
Figure 1. Clinical course: leucocyte count (LC), erythrocyte sedimentation rate (ESR) and temperature.
LC > ll.OOO/mm5; O, ESR > 20mm/h; • , temperature > 38"C.
2
0
Figure 2.
Admdtion Day 3 Day 6
Clinical course: pain as assessed by scoring systems A (53) and B ( • ) .
Table X. Adverse events
Adverse event
Phlebitis
Drug fever
Exanthema
Severe diarrhoea
Moderate diarrhoea
Mild diarrhoea
Nausea + vomiting
Nausea
Mild to moderate
galactorrhoea
Heartburn
No. of cases
48 (47-0%)
1
1
1
12(11-8%)
18 (17-6%)
1
2
2
1
Therapy
discontinued
1
1
1
—
—
—
—
—
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The adverse events observed during the administration of amoxycillin/clavulanate
are detailed in Table X. Amoxycillin/clavulanate therapy had to be discontinued in
three patients, one with a drug fever, one with a rash and one with severe diarrhoea.
Phlebitis was seen in 47-0% of patients and was the most frequent adverse event Since
this problem was not uncommon in patients receiving no amoxycillin/clavulanate, it
may have been associated with the venous cannulation systems used (Venflon and
Abocath). Mild diarrhoea (up to three loose stools per day) was observed in 17-6% of
patients and moderate diarrhoea (four to six loose stools per day) in 11-8%.
Discussion
The diagnosis of acute salpingitis by clinical observation and haematological and
clinical chemical investigations has been shown to be correct in only about 60% of
cases (Jacobson & Westrom, 1969; Chaparro etal., 1978; Kolmorgen, Seidenschnur &
Wergien, 1978; Allen & Schoon, 1983; Kunz & Macciocchi, 1984; Wasserheit etal.,
1986). In clinical studies, confirmation of the diagnosis of acute salpingitis by laparos-
copy is therefore desirable. The fact that the haematological signs of acute salpingitis
do not always match the laparoscopic picture is also demonstrated by our findings. In
only 53-9% of our patients was the leucocyte count (LC) above 11,000/mm3. The
erythrocyte sedimentation rate (ESR) was above 20mm/h in 57-0%, and fever above
38 0°C, in only 27-4% of patients. The laparoscopic assessment of the severity of
infection gave the following results: 43-1% of the cases had a mild, 402% a moderate
and 16-7% a severe infection.
The leading symptom of acute salpingitis is pain, which we assessed using two
scoring systems (TableI). The same approach was chosen by Thompson etal. (1980).
Since LC, ESR and temperature were not outside the normal range in a large number
of hospital patients, pain was chosen as the main criterion to assess the state of
recovery.
In this study we attempted not only to assess the clinical outcome at end of
treatment, but also to follow the time course of recovery. When judged by the criteria
'cured' and 'markedly improved', as defined in Table II, 60% of patients were already
'cured' (free of pain) at day three and 58-0% were 'markedly improved'. At day six,
42-8% were 'cured' and 48-0% 'markedly improved'.
For the final assessment of clinical outcome, pain score A, having greater sensitivity
than pain score B, should preferably be used. Using A, 80-0% of patients were
categorized as 'cure', and 18-0% were 'markedly improved' (whereas 87-0% were
'cured' and 110% 'markedly improved', using B) (Table VI). Assessment of pain by
our scoring system is not, of course, absolutely objective. However, as shown above,
the (objective) laboratory variables do not allow clearcut monitoring of the disease
state. The ESR is the least reliable indicator of therapeutic success as its normalization
lags behind the recovery suggested by other signs.
In 68 (66-7%) of patients a bacterium could be isolated or Ch. trachomatis detected.
Considering the care that was taken during withdrawal, transport and culture of the
samples, and in view of the florid nature of the disease states in these patients, this
number seems low. /?-Haemolytic streptococci group B (23 isolates) and coagulase-
negative staphylococci (22) were found most frequently. Their pathogenic role in acute
salpingitis is, however, questionable.
In eight cases a second antibiotic was added to the treatment regimen (Table IX). In
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two of these patients pain had not decreased after three days of treatment. In a further
patient, who had Ch. trachomatis infection and perihepatitis, antimicrobial chemo-
therapy was changed because the patient had persistent pain in the liver region. This
case was not classified as a failure because pain had already markedly decreased during
therapy with amoxycillin/clavulanate. The nine cases reported as Ch. trachomatis
positive (Table V) do not include three cases categorized as presumably positive. Of all
specimens subjected to direct immunofluorescence staining, no typical cells could be
seen in 6-9% (thus not allowing an assessment). All the cases with Ch. trachomatis
except one showed a good clinical response and no relapse on follow-up. We are aware
that clinical success does not necessarily mean that the pathogens were eradicated
(Sweet, Schachter & Robbie, 1983; Martin, Pastorek & Faro, 1986). These authors
reported persistence of Ch. trachomatis after treatment with cephalosporins, but were
unable to detect this organism after treatment with the extended-spectrum penicillins
ticarcillin and piperacillin. Investigations carried out by Bowie etal. (1981) and Csango
et al. (1985) in urethritis in men showed that eradication of Ch. trachomatis by repeated
administration of high doses of amoxycillin is possible. In a study by Crombleholme
etal. (1988) amoxycillin was at least as effective as erythromycin in treating cervical
infection with Ch. trachomatis in pregnancy. However, at present the addition of an
antibiotic with proven activity against Ch. trachomatis should be considered in cases
where this pathogen has been isolated.
Phlebitis (47-0% of cases) and gastrointestinal symptoms, mainly mild to moderate
diarrhoea (29-4%), were the predominant adverse events. Although the high incidence
of phlebitis may have been associated with the frequent administration of antibiotic in
high doses, phlebitis was also often observed in patients receiving no antibiotics.
Therefore, the techniques of inserting iv catheters, and the material in the Venflon and
Abocath systems we used, may have contributed significantly to the high incidence of
phlebitis. In a series of studies at Swiss hospitals where amoxycillin/clavulanate was
administered in a similar way, phlebitis was seen in only 15-3% of patients (Buchi &
Casey, 1988).
In one case amoxycillin/clavulanate therapy had to be stopped on the third day
because of severe, persistent diarrhoea. Clostridhan difficile was isolated, but no
cytotoxin could be detected. The diarrhoea rapidly resolved following cessation of
amoxycillin/clavulanate therapy, and vancomycin therapy was not necessary. In no
other case with diarrhoea had therapy to be stopped, nor was the culture of a stool
sample considered necessary. In the two patients with galactorrhoea, prolactin serum
levels were normal and mammary pathology was excluded.
Overall, the 95% efficacy of amoxycillin/clavulanate alone in the treatment of acute
salpingitis was very satisfactory (Table VIII). In spite of encouraging in-vivo results on
the efficacy of amoxycillin against Ch. trachomatis, at present an antibiotic with proven
efficacy against this organism should be added in cases where its eradication is
considered important.
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